Literature DB >> 14992106

Endovascular treatment of type B thoracic aortic dissections.

Lars Lonn1, Martin Delle, Marten Falkenberg, Vincenzo Lepore, Hans Klingenstierna, Göran Radberg, Bo Risberg.   

Abstract

PURPOSE: To evaluate the initial experience of endovascular repair of aortic dissections from a single center.
MATERIALS AND METHODS: From June 1999 to March 2002, endovascular stent grafting was performed in 20 high-risk patients (16 to 80 years). Eighteen patients had a type B dissection (14 acute and 4 chronic). Two patients had chronic type A dissection. Preoperative work-up included CT and MRI to evaluate the extent of the dissection, the relation to the left subclavian artery, the size of false and true lumen, and branch complications.
RESULTS: Stent-graft deployment was technically successful in all cases. None was converted to open repair. Three patients died within 30 days, i.e., a 15% mortality rate. Four patients (20%) had a perioperative stroke. Paraplegia was observed in one case. No migration of the stent grafts or endoleaks was observed during the mean follow-up period of 13 months. In all but two patient thrombosis of the false lumen was noted.
CONCLUSIONS: Endovascular treatment of thoracic dissections is feasible. Early results are encouraging. While endovascular repair with stent-grafts is progressing rapidly as a viable strategy for aortic dissections in selected patients careful investigations must continue to focus on its safety. Randomized controlled trials are urgently needed.

Entities:  

Mesh:

Year:  2003        PMID: 14992106     DOI: 10.1046/j.0886-0440.2003.00404.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  1 in total

1.  The treatment of spinal cord ischemia following thoracic endovascular aortic repair.

Authors:  Michael L McGarvey; Michael T Mullen; Edward Y Woo; Joseph E Bavaria; Yanni G Augoustides; Steven R Messé; Albert T Cheung
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.